Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML : single center report of the ENACT trial in Lebanon
スポンサーリンク
概要
- 論文の詳細を見る
- 2012-10-01
著者
-
Abboud Miguel
Department Of Pediatrics American University Of Beirut Medical Center
-
OTROCK Zaher
Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut Medical Center
-
MAHFOUZ Rami
Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center
-
FAHED Zahera
Saint Louis Hospital
-
FARHAT Fadi
Hammoud Hospital University Medical Center
-
ZIADE Azzam
Rafic Hariri University Hospital
-
NASR Fadi
Hotel-Dieu de France University Hospital
-
KASSEM Nader
Al-Rasoul Al-Aazam Hospital
関連論文
- Y-chromosome R-M343 African lineages and sickle cell disease reveal structured assimilation in Lebanon
- Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML : single center report of the ENACT trial in Lebanon